search

Active clinical trials for "Leukemia, Myeloid"

Results 1581-1590 of 2842

Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia...

Acute Myelogenous LeukemiaMyelodysplastic Syndrome

The purpose of this study is to compare the effects, good and/or bad, of posaconazole and micafungin in preventing fungal infections after chemotherapy for acute leukemia or myelodysplastic syndrome. When people take chemotherapy, they are more likely to get infections. Posaconazole has been approved for the prevention of fungal infections in patients who receive induction chemotherapy for acute leukemia and myelodysplastic syndrome. Posaconazole is available only as an oral suspension and has to be given with food. After chemotherapy, many patients are not able to tolerate food or oral medication because of severe mucositis. Patients unable to tolerate food and oral medications cannot take posaconazole. Micafungin is an antifungal medication that is given only intravenously. Micafungin is approved for the treatment of certain fungal infections and for preventing fungal infections in patients who receive bone marrow transplant. The investigators know that micafungin is safe. Micafungin has not been tested for the prevention of fungal infections in patients receiving chemotherapy for acute leukemia and myelodysplastic syndrome. Because micafungin is given by vein, it can be given even in patients who cannot take food or medications by mouth after chemotherapy. In this study the investigators want to compare micafungin to posaconazole when given for the prevention of fungal infections in leukemia and myelodysplastic syndrome patients.

Completed17 enrollment criteria

Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic...

Acute Lymphoblastic LeukemiaAcute Myelocytic Leukemia3 more

The purpose of the study is to determine if participants who receive the GVHD prophylaxis medication pentostatin will have less severe hepatic toxicities than those receiving MTX. The study is estimated to have sufficient statistical power to ascertain at least a 20% improvement in day 42 NCI CTC grade 2 or above hepatic toxicity-free survival in pentostatin recipients.

Completed27 enrollment criteria

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation...

Myelodysplastic SyndromeAcute Lymphocytic Leukemia3 more

Background: One way to treat certain cancers of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very similar but not identical to the patients. One problem with these transplants is that the new immune cells may not work as well in the recipient as they did in the donor. The result may be that the immune system will not work as well. This can increase the risk of severe infections and other complications. Researchers are studying the use of drugs that lower hormone levels and may allow the immune system to recover in a way that improves white blood cell function. In this study they will be looking at the drug leuprolide, a drug that lowers estrogen or testosterone levels, to see if it might improve the function of the newly transplanted cells. Objectives: To determine whether leuprolide improves immune system function after bone marrow transplant from a donor with similarities in their immune cells (matched to each other). To evaluate the effectiveness of a nuclear medicine test with a radiotracer drug 3-deoxy-3 18F-fluorothymidine (FLT) in imaging studies. FLT will be used to image the immune system function in patients who have received bone marrow from the donor. Eligibility: People between 15 (or as young as 9 in those who have gone through puberty) and 55 years of age. These patients must have acute myelogenous leukemia, acute lymphocytic leukemia, high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or chronic myeloid leukemia. They must also be eligible for a bone marrow transplant. Genetically similar donors for the patients who are eligible for a transplant. Design: People taking part in the study will be screened with a physical examination, medical history, blood and urine tests, and imaging studies. Patients who are not in remission or who require a bone marrow donor search may receive chemotherapy first. Donors will provide bone marrow for transplant according to standard bone marrow transplant (BMT) procedures. All women and half of the men will receive regular leuprolide doses 2 weeks before BMT to suppress hormone function. All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy before the bone marrow transplant (depending on age). Recipients will also receive other drugs to prevent transplant rejection and other complications of transplantation. Recipients will be monitored in the hospital for 4 weeks after transplant with blood tests and other studies. Some recipients will have an imaging study with FLT during the protocol. These imaging studies will take place before the transplant, on days 5 and 28 after transplant, and at a later time to be determined by the study researchers. Following discharge, participants will be monitored closely for up to 6 months, with regular but less frequent followup visits for at least 5 years. Study-related medications, including vaccinations for the new immune system, will be provided by the National Institutes of Health during the hospital stay and after discharge.

Completed81 enrollment criteria

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Multiple MyelomaNon-Hodgkin Lymphoma3 more

To determine the maximum tolerated dose (MTD) of OPB-51602

Completed14 enrollment criteria

Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia

Acute Myeloid Leukemia

The purpose of this study is to determine whether tigecycline is safe and which dosage is most effective in the treatment of patients with acute myeloid leukemia.

Completed20 enrollment criteria

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic...

Chronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia

This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.

Completed2 enrollment criteria

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending...

Acute Myelocytic LeukemiaMyelodysplastic Syndrome

Assessment of efficacy of azacitidine to prevent a relapse

Completed29 enrollment criteria

Improving Blood Stem Cell Collection and Transplant Procedures

Myelodysplastic Syndrome (MDS)Chronic Myelogenous Leukemia3 more

Background: - People who have some kinds of cancer can benefit from donated bone marrow stem cells. These stem cells help produce healthy bone marrow and slow or stop the spread of abnormal cells. However, stem cells transplants do not always work. Also, they may have serious side effects that can cause illness or death. The Bone Marrow Stem Cell Transplant Program is studying methods to make stem cell transplant procedures safer and more effective. Objectives: - To test a new procedure that may improve the success and decrease the side effects of stem cell transplants. Eligibility: Individuals 10 to 75 years of age who have a life-threatening illness that may require a stem cell transplant. Healthy siblings who are able to provide stem cells for transplant. Design: Participants will be screened with a medical history, physical exam, and blood and urine tests. Donor procedures: Stem cell donors will start by having apheresis to donate white blood cells. Donors will receive filgrastim shots for 5 days to help move stem cells into the blood for collection. Donors will have another round of apheresis to donate the stem cells for transplant. Recipient procedures: Before the transplant, recipients will have radiation twice a day for 3 days and chemotherapy for 7 days. After the radiation and chemotherapy, recipients will receive the stem cells provided by the donor. After the transplant, recipients will receive the white blood cells provided by the donor. Recipients will be monitored closely for 4 months to study the success of the transplant. They will have more followup visits at least yearly thereafter. Recipients will have a research apheresis prior to transplant and at 3 months.

Completed41 enrollment criteria

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological...

Adult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission46 more

The purpose of this research study is to compare the survival rates of patients with better risk disease undergoing hematopoietic stem cell transplant (HSCT) to the survival rates reported in the medical literature of similar patients undergoing reduced intensity HSCT from matched related donors.

Completed28 enrollment criteria

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation...

LeukemiaMyeloid6 more

This is a phase I/II study of highly selected donor lymphocyte infusions in patients undergoing HLA-haploidentical hemopoietic stem cell transplantation. Patients will be offered "pre-emptive" NK-DLI early after HSCT. Three schedules of NK-cell infusion will be studied: Basel patients (adult and pediatric) will receive NK-DLI on days +40 and +100 (pre-emptive-late); Frankfurt patients (pediatric) will receive NK-DLI on days +3, +40, and +100 (pre-emptive early). Patients not receiving pre-emptive NK-DLI with loss in donor chimerism or with evidence of minimal residual disease will be offered "therapeutic" NK-DLI.

Completed4 enrollment criteria
1...158159160...285

Need Help? Contact our team!


We'll reach out to this number within 24 hrs